Marine compound discovery shows promise of improved drug treatment for COPD patients
Pharmacy researchers at the University of Florida have isolated a new marine compound they believe may lead to improved drug therapies for pulmonary diseases by inhibiting their progression rather than managing their symptoms.
Known as symplostatin 5, the compound was extracted from blue-green algae collected in Cetti Bay, Guam, by Hendrik Luesch, Ph.D., the Frank A. Duckworth eminent scholar chair in drug research and development. The new compound targets an enzyme overactive in chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome, cystic fibrosis and other diseases.
“These compounds can potentially offer a new opportunity to treat COPD and related diseases in a different way and possibly more effectively,” Luesch said.
Elastase is an enzyme that breaks down a variety of proteins. In COPD, where there is excessive enzyme activity, this contributes in part to lung damage and inflammation. The effects of elastase on these processes contribute to the irreversible destruction of lung tissues typically observed in COPD patients.
Lilibeth Salvador, a researcher in Luesch’s Marine Natural Products lab, led the investigation published in Medicinal Chemistry. The study revealed that the blue-green algae prevented elastase-driven changes in bronchial connective tissue cells.
Salvador, who will earn her doctorate from the UF College of Pharmacy in May, uses a soccer analogy to describe how the compound may prove to be a more effective drug therapy.
“By inhibiting this enzyme, we prevent one of the key players in the initiation of COPD. So, we prevent the ball from being relayed on to other players involved in the progression of the disease,” she said.
Blue-green algae investigated by the Luesch lab contain naturally occurring molecules essential for survival in a harsh marine environment. These ingredients are what Luesch believes will lead to a new source of drugs that he hopes to develop for improved treatments for patients suffering from COPD and a host of other diseases.
From his marine samples collected in the Atlantic side of the Florida Keys to as far away as Guam in the Pacific, Luesch has discovered dozens of new promising compounds. His lab has already chemically synthesized several of these natural products and designed and generated similar compounds with improved drug-like properties. Further research funding enables him to continue the drug development process. His early studies show these marine compounds have the right stuff to begin further clinical studies for drugs to treat colorectal, prostate and metastatic breast cancer, enhance bone regeneration and slow the progression of Alzheimer’s disease.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Efficient Recycling Process for Rare Earths Through Bioleaching and Bioaccumulation - Great potential in the recovery of valuable materials from electronic waste: Up to 85% recovery of rare earths achieved in the laboratory
Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration
